Search

An international team of researchers led by Sandra Misale, research associate at the Sloan Kettering Institute, examined the effects of the experimental cancer drug, AMG510, which targets KRAS G12C cell lines, and found that the efficacy of such KRAS G12C inhibitors is lineage-specific. These findings provide a mechanistic understanding of the differences in response to KRAS G12C inhibitor in lung and colorectal cancers.

… Tuesday, May 19, 2020 Background KRAS is one of the most commonly mutated genes in human tumors, including lung, colon and pancreatic cancers. Mutant KRAS has been considered undruggable for decades until the recent development of a new class of covalent inhibitors that are able to inhibit the G12C mutant

Memorial Sloan Kettering Cancer Center (MSK) has been recognized by the American College of Surgeons (ACS) for its commitment to providing optimal surgical care for children and adolescents.

… Tuesday, March 14, 2023 Memorial Sloan Kettering Cancer Center (MSK) has been recognized by the American College of Surgeons (ACS) for its commitment to providing optimal surgical care for children and adolescents. It is the first hospital in the nation to receive the ACS’ Children’s Surgery Verification

Learn how Randy Reif got state-of-the-art care for a benign brain tumor at Memorial Sloan Kettering Cancer Center.

… Wednesday, February 16, 2022 Police officer Randy Reif was trained to handle almost any situation. But nothing could have prepared him for the fight of his life. Randy woke up one day in October 2021 feeling lightheaded. He also noticed changes in his vision. Before long, Randy was on the floor, having

A team of experts at MSK shared their insights on managing blood cancer or a bone marrow transplant in a recent Information Session.

… Monday, June 15, 2020 Concerns around COVID-19 are common in the general population, but cancer patients are also balancing questions about what the pandemic means for their treatment, prognosis, and vulnerability to the virus.  A team of experts at MSK shared their insights on this topic in an Information

Adding immunotherapy to standard treatment both before and after surgery significantly improved outcomes for people with gastric and gastroesophageal adenocarcinoma (G/GEA), according to experts from Memorial Sloan Kettering Cancer Center (MSK). Results from the MATTERHORN trial, a global phase three study, were presented today at the annual American Society of Clinical Oncology meeting and simultaneously published in the New England Journal of Medicine (NEJM).

… Sunday, June 1, 2025 Adding immunotherapy to standard treatment both before and after surgery significantly improved outcomes for people with gastric and gastroesophageal adenocarcinoma (G/GEA), according to experts from Memorial Sloan Kettering Cancer Center (MSK). Results from the MATTERHORN trial,

In an effort to stop tuberculosis (TB) from becoming progressively less treatable worldwide, the National Institutes of Health is funding a research collaboration among six institutions in close alliance. The total funding, provided by the National Institute of Allergy and Infectious Diseases, could be up to $45.7 million over seven years.

… Wednesday, February 18, 2015 In an effort to stop tuberculosis (TB) from becoming progressively less treatable worldwide, the National Institutes of Health has awarded Weill Cornell Medical College more than $6.2 million in first-year funding to support a research collaboration among six institutions

Lymphoma experts Anas Younes, MD and Andrew Zelenetz, MD, PhD discuss the fast evolving research on CAR T cells and checkpoint inhibitors that is yielding the novel treatment options improving both outcomes and quality of life for people with lymphoma.

… Wednesday, May 16, 2018 VIDEO | 05:17 Lymphoma Update: CAR T Therapies and Checkpoint Inhibitors Lymphoma experts Anas Younes, MD and Andrew Zelenetz, MD, PhD discuss the fast evolving research on CAR T cells and checkpoint inhibitors that is yielding the novel treatment options improving both outcomes

A new MSK-led study used single-cell sequencing and other techniques to examine a phenomenon known as “whole-genome doubling” in high-grade serous ovarian carcinoma (HGSOC), the most common and aggressive form of ovarian cancer. The insights could help researchers develop more effective treatment strategies.

… Wednesday, July 16, 2025 Research led by Memorial Sloan Kettering Cancer Center (MSK) is shedding new light on how ovarian cancer evolves — insights that could help researchers develop more effective treatment strategies. While ovarian cancer diagnoses and deaths have decreased over recent decades ,

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Monday, May 17, 2021 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Larry Norton Elected to the American Academy of Arts & Sciences Larry Norton Larry Norton, MD , Senior Vice President, Office of the President; Medical Director, Evelyn H. Lauder Breast

Discovery reveals that the genetic causes of cancer may be more complicated than previously thought.

… Wednesday, May 27, 2020 Summary It turns out that finding driver mutations may be more complicated than previously thought: Nearly a quarter of all tumors have two different mutations in the same gene. A major effort in cancer research is the search for driver mutations in tumors. These mutations are